公开(公告)号：EP1602642A4

公开(公告)日：2006-11-08

申请号：EP04720259

申请日：2004-03-12

申请人： ONO PHARMACEUTICAL CO

发明人： ISHIDA A ,  KUSUDA S ,  NAKAYAMA Y ,  TAJIMA H ,  KIDO T ,  KITAMINE T

IPC分类号： A61P3/04 ,  A61P3/06 ,  C07C251/54 ,  C07D207/20 ,  C07D209/08 ,  C07D211/70 ,  C07D213/30 ,  C07D213/50 ,  C07D213/53 ,  C07D213/55 ,  C07D231/12 ,  C07D233/54 ,  C07D249/08 ,  C07D257/04 ,  C07D277/04 ,  C07D295/13 ,  C07D307/52 ,  C07D319/08 ,  C07D333/22 ,  C07D403/12 ,  C07D407/10 ,  C07D407/12 ,  C07D409/04 ,  C07D417/10 ,  A61K31/357 ,  C07D317/14

CPC分类号： C07D213/30 ,  C07C251/54 ,  C07D207/20 ,  C07D209/08 ,  C07D211/70 ,  C07D213/50 ,  C07D213/53 ,  C07D213/55 ,  C07D231/12 ,  C07D233/54 ,  C07D249/08 ,  C07D257/04 ,  C07D277/04 ,  C07D295/13 ,  C07D307/52 ,  C07D319/08 ,  C07D333/22 ,  C07D403/12 ,  C07D407/10 ,  C07D407/12 ,  C07D409/04 ,  C07D417/10

摘要： A compound represented by the following general formula (I), its salt, its solvate or its N-oxide or prodrugs thereof: (I) wherein R1 and R2 represent each an optionally substituted cyclic group, etc.; W is a spacer having from 1 to 6 carbon atoms in its main chain; X represents -O-, etc.; A represents an optionally substituted cyclic group; Y is a spacer having from 1 to 6 carbon atoms in its main chain, etc.; and Z represents an acidic group. Because of having an activity of controlling peroxisome proliferator-activated receptors, the compounds are useful as preventives/remedies for metabolic errors such as hypercholesteremia and hyperlipoproteinemia, hyperlipemia, arteriosclerosis, hypertension, circulatory diseases, hyperphagia, ischemic heart diseases and so on, HDL cholesterol-elevating agents, LDL cholesterol and/or VLDL cholesterol-lowering agents, and drugs for relieving risk factors of diabetes and metabolic syndrome.